Korean Medication Algorithm Project for Generalized Anxiety Disorder 2009 (III) : Treatment Strategy for Comorbid Conditions.
- Author:
Sang Hyuk LEE
1
;
Jong Chul YANG
;
Ho Suk SUH
;
Joon Yeob LEE
;
Min Sook KIM
;
Chan Hyung KIM
;
Bum Hee YU
Author Information
1. Department of Psychiatry, School of Medicine, CHA University, Seoul, Korea.
- Publication Type:Clinical Trial ; Original Article
- Keywords:
Generalized anxiety disorder;
Pharmacotherapy;
Algorithm;
Comorbidity
- MeSH:
Alprazolam;
Anxiety;
Anxiety Disorders;
Benzodiazepines;
Comorbidity;
Consensus;
Depression;
Expert Testimony;
Humans;
Norepinephrine;
Panic Disorder;
Surveys and Questionnaires;
Serotonin
- From:Journal of Korean Neuropsychiatric Association
2010;49(6):564-569
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: This study investigated the consensus about treatment strategies for comorbid conditions in generalized anxiety disorder (GAD). METHODS: The executive committee of the Korean Medication Algorithm Project for GAD developed questionnaires about treatment strategies for patients with panic disorder based on guidelines or algorithms and clinical trial studies previously published in foreign countries. This study analyzed the treatment strategies for comorbid conditions in GAD. Fifty-five (65%) of 84 experts on a committee reviewing GADs responded to the questionnaires. We classified the consensus of expert opinions into three categories (first-line, second-line, and third-line treatment strategies) and identified the treatment of choice according using a chi2 test and 95% confidence interval. RESULTS: The consensus about treatment strategies in the case of GAD with comorbid depression recommended a selective serotonin reuptake inhibitor (SSRI) and a serotonin norepinephrine reuptake inhibitor (SNRI) as the first-line drug treatment. An SSRI, an SNRI and a benzodiazepine (e.g. alprazolam, clonazepam) are recommended in GAD patients with other comorbid anxiety disorders. CONCLUSION: This study provided information about the consensus among Korean experts with regard to treatment strategies for comorbid conditions of GAD.
